Literature DB >> 30127038

Androgen deprivation therapy for metastatic salivary gland cancer.

Arielle Elkrief1, Ramy Saleh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30127038      PMCID： PMC6102105          DOI： 10.1503/cmaj.180286

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.

Authors:  Heidy C J Jaspers; Berit M Verbist; Rafke Schoffelen; Vera Mattijssen; Piet J Slootweg; Winette T A van der Graaf; Carla M L van Herpen
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

2.  Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.

Authors:  Laura D Locati; Federica Perrone; Barbara Cortelazzi; Salvatore Lo Vullo; Paolo Bossi; Gianpaolo Dagrada; Pasquale Quattrone; Cristiana Bergamini; Paolo Potepan; Enrico Civelli; Carlo Fallai; Silvana Pilotti; Lisa Licitra
Journal:  Head Neck       Date:  2015-06-25       Impact factor: 3.147

3.  Abiraterone in metastatic salivary duct carcinoma.

Authors:  Damien Urban; Danny Rischin; Christopher Angel; Ieta D'Costa; Benjamin Solomon
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

Review 4.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Authors:  Scott A Laurie; Alan L Ho; Matthew G Fury; Eric Sherman; David G Pfister
Journal:  Lancet Oncol       Date:  2010-12-10       Impact factor: 41.316

Review 5.  Adverse effects of androgen deprivation therapy and strategies to mitigate them.

Authors:  Paul L Nguyen; Shabbir M H Alibhai; Shehzad Basaria; Anthony V D'Amico; Philip W Kantoff; Nancy L Keating; David F Penson; Derek J Rosario; Bertrand Tombal; Matthew R Smith
Journal:  Eur Urol       Date:  2014-08-02       Impact factor: 20.096

6.  Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.

Authors:  Nobuko Yamamoto; Shujiro Minami; Masato Fujii
Journal:  Am J Otolaryngol       Date:  2014-07-10       Impact factor: 1.808

7.  Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy.

Authors:  Margaret S Soper; Shawn Iganej; Lester D R Thompson
Journal:  Head Neck       Date:  2013-09-17       Impact factor: 3.147

8.  A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.

Authors:  C Fushimi; Y Tada; H Takahashi; T Nagao; H Ojiri; T Masubuchi; T Matsuki; K Miura; D Kawakita; H Hirai; E Hoshino; S Kamata; T Saotome
Journal:  Ann Oncol       Date:  2018-04-01       Impact factor: 32.976

9.  Overview of major salivary gland cancer surgery in Ontario (2003-2010).

Authors:  Antoine Eskander; Jonathan Irish; Jeremy Freeman; Patrick Gullane; Ralph Gilbert; Patti A Groome; Stephen F Hall; David R Urbach; David P Goldstein
Journal:  J Otolaryngol Head Neck Surg       Date:  2014-12-10

10.  Hormone dependent metastatic salivary gland carcinoma: a case report.

Authors:  Abed Agbarya; Salem Billan; Haitam Nasrallah; Addie Dvir; Lior Soussan-Gutman; Orit Kaidar-Person
Journal:  Springerplus       Date:  2014-07-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.